

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8085858

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SEVEN BRIDGES GENOMICS INC.	07/31/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
<b>Street Address:</b>	601 LEXINGTON AVENUE, 54TH FLOOR
<b>Internal Address:</b>	C/O ORBIMED ADVISORS LLC
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022
<b>PROPERTY NUMBERS Total: 8</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17853102
Application Number:	17933260
Application Number:	18071786
Application Number:	18079195
Application Number:	18132353
Application Number:	18324799
Application Number:	18331293
Application Number:	18329431
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	akwon@cov.com
<b>Correspondent Name:</b>	COVINGTON & BURLING LLP
<b>Address Line 1:</b>	ONE CITY CENTER, 850 TENTH ST NW
<b>Address Line 2:</b>	ATTN: PATENT DOCKET
<b>Address Line 4:</b>	WASHINGTON, D.C. 20001
<b>ATTORNEY DOCKET NUMBER:</b>	034550.00095
<b>NAME OF SUBMITTER:</b>	ASHLEY M. KWON

<b>SIGNATURE:</b>	/Ashley M. Kwon/
<b>DATE SIGNED:</b>	07/31/2023
<b>Total Attachments: 4</b> source=OrbiMed-M51 - Patent Security Supplement (Delayed Draw) Executed#page1.tif source=OrbiMed-M51 - Patent Security Supplement (Delayed Draw) Executed#page2.tif source=OrbiMed-M51 - Patent Security Supplement (Delayed Draw) Executed#page3.tif source=OrbiMed-M51 - Patent Security Supplement (Delayed Draw) Executed#page4.tif	

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of July 31, 2023 (this “Agreement”), is made by SEVEN BRIDGES GENOMICS INC., a Delaware corporation (the “Grantor”), in favor of ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP, a Delaware limited partnership (together with its Affiliates, successors, permitted transferees and permitted assignees, the “Lender”).

W I T N E S S E T H :

WHEREAS, pursuant to the Credit Agreement, dated as of August 1, 2022 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among M51 Bidco, Inc., a Delaware corporation (the “Borrower”), M51 Midco, Inc., as Holdings, and the Lender, the Lender has extended Commitments to make Loans to the Borrower;

WHEREAS, in connection with the Credit Agreement, the Grantor has executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of August 1, 2022 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”);

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (e) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Lender, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Lender, for the Lender’s benefit, a continuing security interest in all of the Grantor’s right, title and interest in and to the Patent Collateral, including each patent and patent application referred to in Item A of Schedule I attached hereto. Notwithstanding anything to the contrary, the Patent Collateral does not include Excluded Assets.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Release of Liens. Upon (a) the sale of Patent Collateral to Persons who are not the Borrower or any Subsidiary thereof in accordance with the Credit Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Patent Collateral (in the case of clause (a)) or (ii) all Patent Collateral (in the case of clause (b)). Upon any such sale or termination, the Lender will, at the Grantor's sole expense, deliver to the Grantor, without any representations, warranties or recourse of any kind whatsoever, all such Patent Collateral held by the Lender hereunder, and execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

SECTION 7. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantor shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g., "pdf" or "tiff") or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

SEVEN BRIDGES GENOMICS INC.

DocuSigned by:

Pio Szamel

0B7BA2018FEC4D9

By: \_\_\_\_\_

Name: Pio Szamel

Title: Vice President and Secretary

**SCHEDULE I**  
to Patent Security Agreement

**Item A. Patents**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Country</b>	<b>Status</b>	<b>Assignee</b>
METHODS AND SYSTEMS FOR IDENTIFYING DISEASE-INDUCED MUTATIONS	17/853,102	6/29/2023	USA	Pending	Seven Bridges Genomics Inc.
METHODS AND SYSTEMS FOR DETECTING SEQUENCE VARIANTS	17/933,260	9/19/2022	USA	Pending	Seven Bridges Genomics Inc.
SYSTEMS AND METHODS FOR ANALYZING CIRCULATING TUMOR DNA	18/071,786	11/30/2022	USA	Pending	Seven Bridges Genomics Inc.
Methods and Systems for Stream-Processing of Biomedical Data	18/079,195	12/12/2020	USA	Pending	Seven Bridges Genomics Inc.
SYSTEMS AND METHODS FOR MITOCHONDRIAL ANALYSIS	18/132,353	4/7/2023	USA	Pending	Seven Bridges Genomics Inc.
SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS	18/324,799	5/26/2023	USA	Pending	Seven Bridges Genomics Inc.
SYSTEMS AND METHODS FOR ANALYZING SEQUENCE DATA	18/331,293	6/8/2023	USA	Pending	Seven Bridges Genomics Inc.
SYSTEMS AND METHODS FOR EPIGENETIC ANALYSIS	18/329,431	6/5/2023	USA	Pending	Seven Bridges Genomics Inc.